Nephrology
FDA/CDC
New drug, finerenone, approved for slowing kidney disease in diabetes
Finerenone (Kerendia) is the first agent approved from a novel class, the nonsteroidal mineralocorticoid receptor antagonists. But its role in...
Conference Coverage
‘Stunning’ twincretin beats semaglutide for A1c, weight reduction in T2D
Head-to-head pivotal trial results show weekly tirzepatide injections surpassed 1 mg semaglutide weekly for A1c reduction and weight loss.
News
Third COVID-19 vaccine dose helped some transplant recipients
All of those with low titers before the third dose had high titers after receiving the extra shot, in case series.
News
Finerenone scores second pivotal-trial success in patients with diabetic kidney disease
FDA/CDC
FDA approves dapagliflozin (Farxiga) for chronic kidney disease
Based on results of the DAPA-CKD trial, the FDA has granted approval for the diabetes drug in patients with CKD at risk for disease progression....
Conference Coverage
Half of patients in hospital for COVID-19 get acute kidney injury
It’s bad news when hospitalized COVID-19 patients develop acute kidney injury, which can prove fatal or can lead to the development or worsening...
Outcomes Research in Review
Lenvatinib Plus Pembrolizumab Improves Outcomes in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma
News
Missed visits during pandemic cause ‘detrimental ripple effects’
ACP president says doctors are already seeing the consequences of postponing care.
News
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
Five new cases of euglycemic diabetic ketoacidosis seen in T2D patients with acute COVID-19 illness.
Conference Coverage
Finerenone’s heart benefits hold up in T2D patients without CVD
In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...